This inventor holds 1 USPTO granted patent. Top assignee: Other. Active years: 2002.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
1 out of 834,601 Years Active: 2002
Title: John K Cowell: Innovator in Telomerase-Targeted Therapies
Introduction
John K Cowell is a notable inventor based in Shaker Heights, OH (US). He has made significant contributions to the field of molecular biology, particularly in the development of therapies targeting telomerase-expressing malignancies. His innovative work has the potential to impact cancer treatment significantly.
Latest Patents
John K Cowell holds a patent for "RNase L activators and antisense oligonucleotides effective to treat telomerase-expressing malignancies." This invention relates to chimeric molecules that comprise an oligonucleotide complementary to a region of the ribonucleotide component of telomerase. These molecules are attached to an activator of RNase L, forming an "activator-antisense complex" that specifically cleaves the ribonucleotide portion of the telomerase enzyme. The invention outlines methods for inhibiting telomerase enzymatic activity using these complexes, which are targeted to the RNA component of telomerase. Furthermore, it describes methods for treating malignant neoplastic diseases where telomerase activity is essential for the growth of malignant cells.
Career Highlights
Throughout his career, John K Cowell has focused on advancing the understanding of telomerase and its role in cancer. His research has led to innovative approaches that could change the landscape of cancer therapies. With a patent portfolio that includes one significant patent, Cowell continues to contribute to the scientific community.
Collaborations
John K Cowell has collaborated with esteemed colleagues such as Robert H Silverman and Seiji Kondo. These partnerships have fostered a collaborative environment that enhances research and development in the field of cancer treatment.
Conclusion
John K Cowell's work in developing RNase L activators and antisense oligonucleotides represents a significant advancement in the fight against telomerase-expressing malignancies. His innovative approaches and collaborations highlight the importance of targeted therapies in modern medicine.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile